TELA Bio, Inc. (NASDAQ:TELA) reported Q2 EPS of ($0.88), $0.28 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $10.12 million.
GUIDANCE:
TELA Bio, Inc. sees FY2022 revenue of $42-45 million, versus the consensus of $42.3 million.